While DNA databases may offer the opportunity to (1) assess population-based prevalence of specific genes and variants, (2) simplify the search for molecular markers, (3) improve targeted drug discovery and development for disease management, (4) refine strategies for disease prevention, and (5) provide the data necessary for evidence-based decision-making, serious scientific and social questions remain. Whether samples are identified, coded, or anonymous, biological banking raises profound ethical and legal issues pertaining to access, informed consent, privacy and confidentiality of genomic information, civil liberties, patenting, and proprietary rights. This paper provides an overview of key policy issues and questions pertaining to biological banking, with a focus on developments in specimen collection, transnational distribution, and public health and academic-industry research alliances. It highlights the challenges posed by the commercialization of genomics, and proposes the need for harmonization of biological banking policies.

1.
Clayton EW, Steinberg KK, Khoury MJ, Thomson E, Andrews L, Lahn MJ, Kopelman LM, Weiss JO: Informed consent for genetic research on stored tissue samples. JAMA 1995;274:1786–1792.
2.
American College of Medical Genetics, Storage of Genetic Materials Committee: Statement on storage and use of genetic materials. Am J Hum Genet 1995;57:1499–1500.
3.
American Society of Human Genetics: DNA banking and DNA analysis: Points to consider. Am J Hum Genet 1987;42:781–783.
4.
Task Force on Genetic Testing. NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Project, Baltimore 1997.
6.
Sugarman J, Reisner EG, Kurtzberg J: Ethical aspects of banking placental blood for transplantation. JAMA 1995;274:1783–1785.
7.
Wiley JM, Kuller JA: Storage of newborn stem cells for future use. Obstet Gynecol 1997;89:300–303.
8.
Enriquez J: The life science revolution: A rough map. J BioLaw Bus 2000;4:4.
9.
Blatt RJR: Banking biological collections. Editorial. BioLaw Bus 1998;2(1).
10.
Gmach M, Haslberger A: International Symposium on Genetic Testing in Europe: Harmonisation of Standards and Regulations, Vienna, 1998.
11.
Boyle P: Shaping Priorities in Genetic Medicine. Hastings Center Report Special Supplement, May–June 1995.
12.
Lowrance WW: Data protection in transborder flows of health research data. Paris, OECD, 1999.
13.
Declich S, Carter AO: Public health surveillance: Historical origins, methods and evaluation. Bull World Health Organ 1994;72:285–304.
14.
Ronchi E: Genetic testing: Policy issues for the new millennium. J BioLaw Bus 2001;4(3).
15.
OECD: Genetic Testing Policy Issues for the New Millennium. Paris, OECD, 2000.
16.
Khoury MJ: From genes to public health: The applications of genetic technology in disease prevention. Am J Public Health 1996;86:1717–1722.
17.
Khoury MJ: Genetic epidemiology and the future of disease prevention and public health. Epidemiol Rev 1997;19:175–180.
18.
Khoury MJ, Dorman JS: The human genome epidemiology network. Am J Epidemiol 1998;148(1).
19.
Khoury MJ, Wagener DK: Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. Am J Hum Genet 1995;56:835–844.
20.
Sibthorpe B, Kliewer E, Smith L: Record linkage in Australian epidemiological research: Health benefits, privacy safeguards and future potential. Aust J Public Health 1995;19:250–257.
21.
Dahm L: Using DNA profile as the unique patient identifier in the community information network: Legal implications. J Marshall J Comput Info Law 1997;15:227.
22.
Carter P: Health information privacy: Can Congress protect confidential information in the ‘information age’. Wm Mitchell Law Rev 1999;25.
23.
Donaldson MS, Lohr KN (eds): Health Data in the Information Age: Use, Disclosure and Privacy. Committee on Regional Health Data Networks, Institute of Medicine, National Academy of Sciences, 1994.
24.
Winickoff D: Biosamples, genomics, and human rights: Context and content of Iceland’s Biobanks Act. J BioLaw Bus 2001;4(2).
25.
Annas GJ: Rules for research on human genetic variation – Lessons from Iceland. N Engl J Med 2000;342:1830–1833.
27.
Hodge J: Implementing modern public health goals through government: An examination of new federalism and Public Health Law. J Contemp Health Law Policy 1997;14:93.
28.
Gostin L, Lazzarini Z, Flaherty KM: Legislative survey of State confidentiality laws, with specific emphasis on HIV and immunization. www.epic-org/privacy/medical/cdc_survey.html.
29.
Gostin L: Genetic privacy. J Law Med Ethics 1995;23:320–330.
30.
Rothstein M: Genetic privacy and confidentiality: Why are they so hard to protect. J Law Med Ethics 1998;26:198–204.
31.
Rothstein M (ed): Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic Era. New Haven, Yale University Press, 1997.
32.
Baird PA: Identifying people’s genes: Ethical aspects of DNA sampling in populations. Perspect Biol Med 1995;38:159–166.
33.
Dash JF: Privacy concerns regarding Government use of genetic information. J BioLaw Bus 1999;2(4).
34.
Miller PS: Is there a pink slip in my genes? Genetic discrimination in the workplace. J Health Care Law Policy 200;3:225–265.
35.
Holtzman N: Genetic screening and public health (editorial). Am J Public Health 1997;87:1275–1277.
36.
Holtzman N, Watson MS: Promoting safe and effective genetic testing in the United States, Final report of the Task Force on Genetic Testing. NIH-DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research, 1999, vol 2(5), pp 388–390.
37.
Annas GL: Privacy rules for DNA databanks: Protecting coded ‘future diaries’. JAMA 1993;270:2346–2350.
38.
Pollack A: Company seeking donors of DNA for ‘gene trust’. New York Times, Aug 1, 2000.
39.
Weiss R: Firm cuts access to gene data. Boston Globe, Dec 9, 2000, A4.
40.
Omenn GS: The genomic era: A crucial role for the public health sciences. Environ Health Perspect 2000;108:A204–205.
41.
Court J: Mapping of human genome raises serious issues of individual rights vs. corporate rights. J BioLaw Bus 2001;4(4).
42.
Greely HT: The control of genetic research: Involving the ‘groups between’. Houston Law Rev 1997;33:1397, 1408–1410.
43.
Taylon AL: Globalization and biotechnology: UNESCO and an international strategy to advance human rights and public health. Am J Law Med 1999;25:481.
44.
Herman N: The difficult search for and equilibrium between data protection and (public) health protection. Acta Clin Belg 1999;54(3).
45.
www.nbac.nih.gov.
46.
HUGO: Statement of DNA sampling, control and access, Feb 1998.
47.
(a) OECD: Recommendations concerning Guidelines Governing the Protection of Privacy and Transborder Flows of Personal Data. Paris, OECD, 1980. 47 (b) OECD: OECD Guidelines for the Security of Information Systems. Paris, OECD, 1992.
48.
Ethical Aspects of Human Tissue Banking Opinion – European group on ethics in science and technology to the European commissions. July 1998.
49.
American Society of Human Genetics, Board of Directors: Statement on informed consent for genetic research. Am J Hum Genet 1996;59:471–474.
50.
Gold RL, Lebel RR, Mearns EA, Dworkin RB, Hadro T, Burns JK: Model consent forms for DNA linkage analysis and storage. Am J Med Genet 1993;47:1223–1224.
51.
Triber G: Prospecting for genetic gold: Should groups that contribute DNA for genetic research be compensated? J BioLaw Bus 1998;2(1).
52.
Stephenson J: Pathologists enter debate on consent for genetic research on stored tissue. JAMA 1996;275:503–504.
53.
Knoppers BM: Confidentiality in genetic testing: Legal and ethical issues in an international context. Med Law 1993;12:573–582.
54.
Knoppers BM, Laberge CM: Research and stored tissues: Persons as samples, samples as persons. JAMA 1995;274:1806–1807.
55.
Knoppers BM, Hirtle M, Lormeau S, Laberge CM, Laflamme M: Control of DNA samples and information. Genomics 1998;50:385–401.
56.
McEwen JE, Reilly PR: Setting standards for DNA banks: Toward a model code of conduct. Microb Comp Genomics 1996;1:165–177.
57.
Reilly PR, Boshar MF, Holtzman SH: Ethical issues in genetic research: Disclosure and informed consent. Nat Genet 1997;15:16–20.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.